A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: LY2216684
DRUG: Methylphenidate
DRUG: Placebo (tablet)
DRUG: Placebo (capsule)

Sponsor

Eli Lilly and Company